Syngene International Limited – Investor Presentation Summary

Key Operational Highlights

  • Siddharth Mittal assumed charge as Managing Director & CEO on July 1, 2026.
  • Signed Memorandum of Understanding with BRIC-Translational Health Science and Technology Institute for joint operational partnership in early and late-phase clinical development, translational research and bioanalytical sciences.
  • Enhanced Syn.AI platform with gigascale virtual screening capabilities and AI-driven de novo design capabilities.
  • Featured in TIME Magazine and Statista's "World's Most Sustainable Companies 2026" ranking for second consecutive year, ranked among top 750 most sustainable companies globally.
  • Total headcount: 8,373 employees including 5,778 scientists.
  • 92% energy from renewable sources.

Key drivers of operational performance: Reduced offtake from a major LMCDMO client, ongoing cost optimization initiatives, and forex hedge loss.

Segment-wise Performance

Not Specified

Financial Highlights

Revenue: Rs 736 Cr (Q1 FY27)

EBITDA: Rs 116 Cr (Q1 FY27)

PAT, before exceptional items: Rs 1 Cr (Q1 FY27)

PAT, after exceptional items: Rs -9 Cr (Q1 FY27)

Margins: Operating EBITDA margin 12% (Q1 FY27), down from 24% in Q1 FY26

YoY/QoQ comparison: Revenue down 16% YoY; Operating EBITDA margin down from 24% to 12% YoY

Drivers of financial performance: Lack of offtake from major LMCDMO client and forex hedge loss, partially offset by cost optimization initiatives.

Key Risks: Not explicitly disclosed in presentation.

Geographical Revenue Split

Not Specified

Balance Sheet Snapshot (as of June 30, 2026)

Shareholders' funds: Rs 4,866 Cr

Net Fixed assets: Rs 4,010 Cr

Other net assets: Rs -685 Cr

Net cash/(debt): Rs 1,541 Cr (net cash position)

Financial Health Insights: Strong net cash position of Rs 1,541 Cr.

Capex & Cash Flow Health

Not Specified for Q1 FY27

Strategic & R&D Initiatives

Investments in Innovation: Enhanced Syn.AI platform with gigascale virtual screening and de novo design capabilities; Acquired 17 acres land in Hyderabad; Acquired biologics site in Baltimore, USA; Investments in peptides and ADCs capabilities.

Expected impact on growth: Not quantified in presentation.

Strategic Rationale: Establishing seamless, one-stop-shop capability from drug discovery to commercial production; Expanding into high-growth markets and emerging modalities.

Industry Trends & Business Environment

Macro/Industry Trends: Growing global demand for emerging modalities such as peptides and ADCs.

Impact on Company: Alignment with global demand trends through capability investments.

Management Commentary & Growth Outlook

Strategic Outlook: Expect degrowth in first half of fiscal year, with business momentum improving in second half.

FY Guidance: Single-digit revenue degrowth in rupee terms for full year; EBITDA margins in the mid-20s.

Market Share Targets: Not specified.

Risks and Opportunities: Not explicitly highlighted beyond forward-looking statements disclaimer.

ESG Updates

  • 92% energy from renewable sources
  • 61% reduction of SBTi Scope 1 & 2 emissions, exceeding target of 54.6%
  • 73,741 tCO2e of GHG emissions avoided
  • 97% of total hazardous and non-hazardous waste recycled
  • Zero waste to direct landfill
  • 58% YoY freshwater savings achieved
  • 1,14,633 KL fresh water saved from recycling, reusing and rainwater harvesting
  • 2,231 KL rainwater harvested
  • 27% women representation overall and 19% women in senior management